Last updated: March 7, 2024
Sponsor: iRxReminder
Overall Status: Active - Recruiting
Phase
N/A
Condition
Dyskinesias
Tardive Dyskinesia
Treatment
TDtect
Clinical Study ID
NCT06011408
#23-002
R43MH114763
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: For the non-TD group:
- Prescribed and taking an antipsychotic medication for 90-days or longer.
- Tardive Dyskinesia symptoms if present are not from Parkinsons, Tourette's syndrome,Huntington disease.
- Signed an informed consent.
- Speaks English fluently.
Exclusion
Exclusion Criteria:
- Suffered a moderate or severe head injury in the last year;
- History of a learning disorder or developmental disability that would inhibit apatient from completing the TD protocol.
- Severe visual impairment that is cannot be corrected by glasses or contacts.
Study Design
Total Participants: 300
Treatment Group(s): 1
Primary Treatment: TDtect
Phase:
Study Start date:
May 30, 2023
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Fermata Helath
Brooklyn, New York 10038
United StatesActive - Recruiting
Charak Research Center
Garfield Heights, Ohio 44125
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.